(secondQuint)The Safety and Effectiveness of Bis-POM PMEA in HIV-Infected Patients.

 Patients are randomized to receive bis-POM PMEA at one of three fixed dose levels or placebo daily for 2 weeks.

 At each dose level, nine patients receive bis-POM PMEA and three patients receive placebo.

.

 The Safety and Effectiveness of Bis-POM PMEA in HIV-Infected Patients@highlight

To study the safety, tolerance, single and multiple dose pharmacokinetics, and anti-HIV activity of bis-POM PMEA ( adefovir dipivoxil ) versus placebo when administered orally on a daily basis for 2 weeks to HIV-infected patients.

